Messenger RNA (mRNA) vaccines are a revolutionary technology in the field of human medicine and are currently being considered to be utilised in veterinary work. Their main strengths include the ability to induce humoral as well as cellular immunity, their short production cycles and their relatively acceptable safety profiles. molecular instability has been identified to be one of the most significant obstacles to the translation of these advantages into veterinary practise, which is not unique to veterinary medicine, but is also a serious concern with human mRNA vaccines development and storage. The possible constraints related to the veterinary use of mRNA vaccines include issues with the delivery system, potential species-related differences in immunogenicity, scalability of production, use of and dependence on cold-chain logistics. Though these considerations have not been currently determined to be significant barriers in the field of veterinary medicine, the active work done in the field of (LNP) formulations, thermostable preparations, and self-amplifying mRNA platforms in the period of 2020-2025 helps to have them mitigated. to enhance the attempts to resolve these problems mRNA vaccines have shown protection against rabies, porcine coronaviruses and feline infectious peritonitis virus, but poultry models have shown good immune responses to Marek’s Disease and avian influenza. The above case studies indicate that the veterinary mRNA vaccines have the potential to transform the field by offering customizable, fast deployable and cost effective alternatives to traditional vaccines. The future research directions include to eliminate the use of a cold-chain to improve the stability of RNAdistribution.